Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Hepatocellular Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Biological: Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta

Registration Number: NCT01628640

Lead Sponsor: Mayo Clinic

Brief Summary: This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus expressing interferon beta in treating patients with liver cancer or solid tumors with lesions that have spread to other parts of the body and do not respond to treatment. The study virus has a gene inserted into it which will allow production of interferon beta, which is a substance that will restrict the spread of the virus to tumor cells and not healthy cells. It will also have some independent anti-cancer activity. Although the primary goal of this study is to evaluate the safety of delivery of this viral agent to people, patients may benefit clinically by having shrinkage or stabilization of their tumor or reduction in their cancer related symptoms (e.g., pain). Funding Source - FDA OOPD.

Detailed Description: PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) of recombinant vesicular stomatitis virus-expressing interferon-beta (VSV-IFN-beta) in patients with hepatocellular carcinoma (HCC) refractory or intolerant to sorafenib therapy and patients with advanced solid tumors with liver predominant locally advanced/metastatic treatment refractory disease. (Arm A) II. To determine the maximum tolerated dose (MTD) of VSV-IFN-beta in patients with advanced solid tumors with subcutaneous/cutaneous lesions. (Arm B)

SECONDARY OBJECTIVES:

I. To estimate the tumor response rate, injected lesion (TNi) and distant lesion (TNd) necrosis rate (with TNi and TNd response defined as \>= 30% increase in necrosis from baseline) and overall survival. (Arm A)

TERTIARY OBJECTIVES:

I. To determine the pharmacokinetic (PK) profile of VSV-IFN-beta in patients with HCC by or advanced solid tumors with liver predominant disease or subcutaneous/cutaneous lesions by measurement of VSV-IFN-beta in blood by reverse transcriptase polymerase chain reaction (RT-PCR).

II. To characterize the pharmacodynamics (PD) of VSV-IFN-beta by way of measuring serum interferon-beta and also VSV-RT-PCR of VSV-IFN-beta listed above.

III. Assess CD8+ T cell (both general and VSV-hIFN-beta specific) and natural killer (NK) cell responses.

IV. Assess status of human interferon beta pathway pre/post therapy in tumor/normal liver tissue (status of IFN-beta, interferon stimulated gene factor 3 \[ISGF3 complex constituting signal transducer and activator of transcription (STAT)1/2 and p48 (ISGF3 gamma)\]).

V. Assess phosphorylation of STAT1/2 post-therapy. VI. Evaluate transcription of interferon mediated genes (protein kinase R, the death receptor-tumor necrosis factor \[TNF\]-related apoptosis-inducing ligand \[TRAIL\], 2'-5' oligoadenylate/ribonucleic acid \[RNA\]se L proteins, heat shock proteins \[Hsp 60/70/90\], major histocompatibility class antigens and interferon regulatory factor \[IRF\]-7).

VII. Assess presence of VSV in tumor/normal liver subsequent to administration of VSV-human IFN-beta (hIFN- beta).

VIII. For HCC patients only, assess preliminary relationships between hepatitis C genotype (in those patients that are hepatitis C positive) and any evidence of anti-tumor efficacy.

OUTLINE: This is a dose-escalation study. Patients are assigned to 1 of 2 arms.

ARM A: Patients with hepatocellular carcinoma or advanced solid tumor with liver lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in a single tumor location on day 1.

ARM B: Patients with advanced solid tumor with subcutaneous/cutaneous lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in up to 5 lesions on day 1.

After completion of study treatment, patients are followed up every 4 weeks for 3 years.

Recruitment & Eligibility

Status: ACTIVE_NOT_RECRUITING

Sex: All

Target Recruitment: 17

Inclusion Criteria

ARM A: Histologically or cytologically confirmed hepatocellular carcinoma that is refractory (by Response Evaluation Criteria in Solid Tumors [RECIST] or modified [m]RECIST criteria or with unequivocal clinical progression of disease) to or intolerant (defined as inability to administer further sorafenib due to drug related toxicities) of sorafenib based therapy or advanced solid tumor with liver predominant disease burden that has progressed on or is intolerant to standard
ARM A: Absolute neutrophil count (ANC) >= 1000/mm^3
ARM A: Platelet count >= 80,000/mm^3
ARM A: Hemoglobin >= 10 g/dl
ARM A: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x ULN
ARM A: Creatinine =< 1.5 x ULN
ARM A: Total bilirubin =< 1.5 x ULN
ARM A: International normalized ratio (INR) =< 1.5 x ULN
ARM A: Activated partial thromboplastin time (aPTT) =< 1.5 x ULN
ARM A: Ability to provide informed written consent
ARM A: Willingness to return to Mayo Clinic in Arizona for follow-up
ARM A: Life expectancy >= 12 weeks
ARM A: Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
ARM A: Willingness to provide all biological specimens as required by the protocol
ARM A: Negative serum pregnancy test =< 7 days prior to registration for women of childbearing potential only
ARM A: Child Pugh Score A or B7 (patients with ascites must have paracentesis performed within scope of standard of care, to be able to successfully perform intratumoral injection procedure)
ARM A: The patient and their partner agree to use a barrier method of contraception during the study and 4 months following end of active treatment
ARM A: Disease burden in liver not affecting more than 25% of liver
ARM A: Predominant intrahepatic burden (> 75%) of disease (i.e. patients with widespread extrahepatic disease to organs other than the liver will not be included)
ARM B: Histologically or cytologically confirmed solid tumor with subcutaneous/cutaneous lesions that is refractory (RECIST or with unequivocal clinical progression of disease) to or intolerant to standard therapy
ARM B: Absolute neutrophil count (ANC) >= 1000/mm^3
ARM B: Platelet count >= 100,000/mm^3
ARM B: Hemoglobin >= 10 g/dl
ARM B: AST/ALT =< 2.5 x ULN
ARM B: Creatinine =< 1.5 x ULN
ARM B: Total bilirubin =< 1.5 x ULN
ARM B: INR =< 1.5 x ULN
ARM B: aPTT =< 1.5 x ULN
ARM B: Ability to provide informed written consent
ARM B: Willingness to return to Mayo Clinic in Arizona for follow-up
ARM B: Life expectancy >= 12 weeks
ARM B: ECOG performance status (PS) 0 or 1
ARM B: Willingness to provide all biological specimens as required by the protocol
ARM B: Negative serum pregnancy test =< 7 days prior to registration for women of childbearing potential only
ARM B: Child Pugh Score A
ARM B: The patient and their partner agree to use a barrier method of contraception during the study and 4 months following end of active treatment
ARM B: Disease burden in liver not affecting more than 25% of liver

Exclusion Criteria

ARM A: Uncontrolled infection
ARM A: Systemic anti-cancer therapy =< 4 weeks prior to registration
ARM A: Known human immunodeficiency virus (HIV) infection
ARM A: Other concurrent chemotherapy, immunotherapy, radiotherapy, or investigational therapy
ARM A: Pregnant or nursing women
ARM A: History of bone marrow or solid organ transplantation
ARM A: Patient for whom surgical resection or liver transplantation would be more appropriate
ARM A: Any condition, which in the opinion of the investigator would render the patient unsuitable to participate in the study
ARM A: Any corticosteroid use =< 28 days prior to registration
ARM A: Any radioembolization or transarterial chemoembolization (TACE) =< 84 days prior to registration
ARM B: Uncontrolled infection
ARM B: Systemic anti-cancer therapy =< 4 weeks prior to registration
ARM B: Known HIV infection
ARM B: Other concurrent chemotherapy, immunotherapy, radiotherapy, or investigational therapy
ARM B: Pregnant or nursing women
ARM B: History of bone marrow or solid organ transplantation
ARM B: Patient for whom surgical resection or liver transplantation would be more appropriate
ARM B: Any condition, which in the opinion of the investigator would render the patient unsuitable to participate in the study
ARM B: Any corticosteroid use =< 28 days prior to registration
ARM B: Any radioembolization or TACE =< 84 days prior to registration

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm B (viral therapy in multiple locations)	Laboratory Biomarker Analysis	Patients with advanced solid tumor with subcutaneous/cutaneous lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in up to 5 cutaneous, subcutaneous, or soft tissue tumor lesions on day 1.
Arm A (viral therapy in single tumor location)	Laboratory Biomarker Analysis	Patients with hepatocellular carcinoma or advanced solid tumor with liver lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in a single tumor location on day 1.
Arm A (viral therapy in single tumor location)	Pharmacological Study	Patients with hepatocellular carcinoma or advanced solid tumor with liver lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in a single tumor location on day 1.
Arm A (viral therapy in single tumor location)	Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta	Patients with hepatocellular carcinoma or advanced solid tumor with liver lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in a single tumor location on day 1.
Arm B (viral therapy in multiple locations)	Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta	Patients with advanced solid tumor with subcutaneous/cutaneous lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in up to 5 cutaneous, subcutaneous, or soft tissue tumor lesions on day 1.
Arm B (viral therapy in multiple locations)	Pharmacological Study	Patients with advanced solid tumor with subcutaneous/cutaneous lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in up to 5 cutaneous, subcutaneous, or soft tissue tumor lesions on day 1.

Primary Outcome Measures

Name	Time	Method
Best tumor response, defined as the best objective status recorded among patients with measurable disease at baseline using Response Evaluation Criteria in Solid Tumors version 1.1	From the start of the treatment until disease progression, assessed up to 3 years	Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease in this patient population (overall, by dose level, and by disease type). Examined in an exploratory and hypothesis-generating fashion.
Incidence of adverse events, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0	Up to 3 years	All eligible patients that have initiated treatment will be considered evaluable for assessing adverse event rate(s). The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed by dose level to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. Examined in an exploratory and hypothesis-generating fashion.
Maximum tolerated dose, defined as the highest dose at which no more than 1/6 patients experiences dose limiting toxicities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0	4 weeks	Dose limiting toxicities defined as an adverse event during the first 4 weeks following injection. A modified "3+3" Fibonacci dose escalation scheme will be used Examined in an exploratory and hypothesis-generating fashion.
Overall survival	From registration to death due to any cause, assessed up to 3 years	The distribution of survival time will be estimated using the method of Kaplan-Meier (overall, by dose level, and by disease type). Examined in an exploratory and hypothesis-generating fashion.
Tumor necrosis	Up to 3 years	Injected lesion and distant lesion necrosis rate will be defined as injected lesion and distant lesion \>= 30% increase in necrosis from baseline, respectively. Frequency and relative frequency will be computed for each (overall, by dose level and by disease type). This analysis will be conducted in hepatocellular carcinoma patients only.

Secondary Outcome Measures

Name	Time	Method

Trial Locations

Locations (1): Mayo Clinic in Arizona
🇺🇸
Scottsdale, Arizona, United States

Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors

Recruitment & Eligibility

Study & Design

Trial Locations

Instant Trial Alerts

Instant Trial Alerts